Adavosertib Liposomes, Formulation WD4
995 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 1142 - DLL-0005-A1-2ML
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 2mL
Parameters
| Additional information | 250 mM Ammonium Sulfate, pH 5.5 |
|---|
DLL-0005-A1-10ML
Adavosertib Liposomes, Formulation WD4
PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.
4995 €
DLL-0005-A1-2ML
Adavosertib Liposomes, Formulation WD4
PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.
995 €
HY-10993
Adavosertib
Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
779.3 €
DLL-0012-1B-1MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
795 €
DLL-0012-1B-5MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1195 €
DLL-0012-1C-1MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
795 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025
By: Author , 2 Comment
Icke-steroida antiinflammatoriska läkemedel – viktig information om populära läkemedel
22 July 2025